The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus

Mok, Chi Chiu; Hamijoyo, Laniyati; Kasitanon, Nuntana; Chen, Der Yuan; Chen, Sheng; Yamaoka, Kunihiro; Oku, Kenji; Li, Mengtao; Zamora, Leonid; Bae, Sang Cheol; Navarra, Sandra V.; Morand, Eric F; Tanaka, Yoshiya

doi:10.1016/s2665-9913(21)00009-6

Cited by 43 publications

(44 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To this end, the APLAR recommends routine screening for HBsAg before immunosuppression in SLE patients. Pre‐emptive antiviral therapy should be given to HBV carriers 16 …”

Section: Resultsmentioning

confidence: 99%

“…Although there are no similar data available in patients with SLE, the risk of hepatitis B reactivation in those with past/resolved infection is expected to be increased in the setting of B‐cell depleting therapy. Aligned with international guidelines, 32‐34 in SLE patients receiving B‐cell depleting therapies or intensive immunosuppression (eg, cyclophosphamide‐based combination regimens), screening and pre‐emptive treatment of past/resolved HBV infection (HBsAg negative/anti‐HBc‐IgG positive/HBV‐DNA positive) is recommended 16 …”

Section: Resultsmentioning

confidence: 99%

“…As risk factors for HCV infection may not be apparent from medical history, routine screening for anti‐HCV antibody is recommended before starting immunosuppressive therapy 16 . In patients with active HCV infection, co‐administration of immunosuppression and antiviral therapy may be considered.…”

Section: Resultsmentioning

confidence: 99%

“…In view of the higher prevalence of TB in Asia and the increased risk of SLE patients developing this infection, active TB should be excluded before immunosuppression in SLE patients. However, routine screening and treatment of latent TB was not recommended in the APLAR SLE management consensus because of the lack of evidence of the risk‐benefit ratio of isoniazid prophylaxis in SLE patients 16 …”

Section: Resultsmentioning

confidence: 99%

“…The Asia‐Pacific League of Associations for Rheumatology (APLAR) SLE special interest group developed consensus recommendations for the management of SLE in the Asia‐Pacific region. By means of a Delphi exercise that involved 29 key rheumatologists and nephrologists, and 3 SLE patients, steered by a group of 13 rheumatologists from different APLAR regions, 34 consensus recommendations were formulated to serve as a guide to specialists, family physicians, specialty nurses, and other healthcare professionals 16 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

et al. 2021

Self Cite

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a more common autoimmune rheumatic disease in the Asia‐Pacific region. The prognosis of SLE remains unsatisfactory in some Asian countries because of delayed diagnosis, limited access to medications, increased complications and issues of tolerability and adherence to treatment. The Asia‐Pacific League of Associations for Rheumatology SLE special interest group has recently published a set of consensus recommendations on the management of SLE for specialists, family physicians, specialty nurses, and other healthcare professionals in the Asia‐Pacific region. This article reports a systematic literature review of the infective complications of SLE in Asia and evidence for prevention of these infections by pre‐emptive antimicrobial therapy and vaccination.

show abstract

“…To this end, the APLAR recommends routine screening for HBsAg before immunosuppression in SLE patients. Pre‐emptive antiviral therapy should be given to HBV carriers 16 …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Effect of Shared Decision‐Making on Trust in Physicians in the Management of Systemic Lupus Erythematosus: The Trust Measurement for Physicians and Patients With Systemic Lupus Erythematosus Prospective Cohort Study

Yoshimi,

Yajima,

Hidekawa

et al. 2024

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveFew studies have explored whether the involvement of patients in shared decision‐making (SDM) is beneficial to the management of systemic lupus erythematosus (SLE). Therefore, this study investigated the relationship between patient participation in SDM and their trust in physicians using data from the TRUMP2‐SLE study.MethodsData regarding the nine‐item Shared Decision‐Making Questionnaire (SDM‐Q‐9 scores), Trust in Physician Scale (TIPS) scores, and Abbreviated Wake Forest Physician Trust Scale (A‐WFPTS) scores for interpersonal trust in a physician and trust in the medical profession were collected from patients with SLE who visited the outpatient clinics of five facilities in Japan through a self‐administered questionnaire. The relationships between these scores were analyzed by general linear models with cluster‐robust variance.ResultsThis study included 433 patients with SLE. The median baseline TIPS and A‐WFPTS (attending physician version) scores were 82 (73–93) and 80 (70–95), respectively. A higher baseline SDM‐Q‐9 score was correlated with an increase in the TIPS score at 1 year (coefficient per 10‐pt increase, 0.94 pt [95%CI 0.16–1.72]). A higher baseline SDM‐Q‐9 score was correlated with a higher A‐WFPTS score for interpersonal trust (coefficient per 10‐pt increase, 2.20 pt [1.44‐2.96]). The baseline SDM‐Q‐9 score was also correlated with an increase in the general physician version of A‐WFPTS score at 1 year (coefficient per 10‐pt increase, 1.29 pt [0.41–2.18]).ConclusionEngagement of patients with SLE in SDM elevates their trust in the attending physicians and healthcare providers, potentially enhancing doctor‐patient relationships and overall healthcare trust.

show abstract

Nutraceuticals in Inflammatory Autoimmune Diseases

Annamma,

Azim,

Ashmawy

2024

Food Bioactive Ingredients

View full text Add to dashboard Cite

The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus

Cited by 43 publications

References 121 publications

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

Effect of Shared Decision‐Making on Trust in Physicians in the Management of Systemic Lupus Erythematosus: The Trust Measurement for Physicians and Patients With Systemic Lupus Erythematosus Prospective Cohort Study

Nutraceuticals in Inflammatory Autoimmune Diseases

Contact Info

Product

Resources

About